An inhibitor that could overcome gefitinib resistance in non-small cell lung cancer acting against multiple targets, including PI3-K, ERK1/2, and Aurora A and B, was discovered recently by using these strategies [45]. Here, MAPK3 is linked to non-small cell lung carcinoma.